

## Hallek, Michael, Univ.-Prof. Dr. med.

Address 19.07.1959, German, male  
University Hospital of Cologne, Department I of Internal Medicine  
Kerpener Str. 62, 50937 Cologne  
Phone: +49 (0) 221 478 39707  
E-mail: [michael.hallek@uk-koeln.de](mailto:michael.hallek@uk-koeln.de)

### Academic education

1998 Board examination hematology and oncology  
1996 Board examination internal medicine  
1978 - 1985 Medical School, University of Regensburg and Technical University Munich

### Scientific degrees

2003 - present C4-Professor, University of Cologne, Department of Internal Medicine  
1999 - 2003 C3-Professor, University of Munich  
1995 Habilitation, University of Munich  
1986 MD Thesis, University of Munich  
1985 Graduation from Medical School, Technical University Munich

### Scientific career

2007 - present Director, Center for Integrated Oncology (CIO), University of Cologne; founding chairman 2018-2022 CIO Aachen Bonn Cologne Düsseldorf  
1998 - 2005 Head, Clinical Cooperation Group GSF (Helmholtz-Institute) Munich  
1995 - 2003 Senior Consultant, University of Munich  
1994 - 2005 Research Group Leader, Gene Center Munich  
1985 - 2003 Training in pharmacology, internal medicine, hematology and oncology, Technical University and University of Munich  
1990 - 1992 Research Associate, Dana Farber Cancer Institute, Harvard Medical School, USA

### Honors/ Awards/ Memberships

2023 - present Chairman, Council for Health and Care of the Federal Government (Sachverständigenrat der Bundesregierung)  
2022 - present Speaker, CRC 1530 on Elucidation and targeting of pathogenic mechanisms in B cell malignancies  
2022 Chairman, Scientific Board of the German Chamber of Physicians  
2021 - present Member, Scientific Council of the German Government (Wissenschaftsrat)  
2021 Henry Kaplan Memorial Lecture and Prize of the International Conference on Malignant Lymphoma  
2020 - present Associate Editor of *Blood*  
2019 - present Strategy Advisory Board "National Decade against Cancer", Federal Ministry of Education and Research (BMBF)  
2019 - present President, Walter-Siegenthaler Society  
2019 José Carreras Award of the European Hematology Association  
2018 - present Chairman Scientific Committee, European School of Hematology, Paris  
2018 Ham-Wasserman Lecture, American Society of Hematology  
2017 German Cancer Award  
2016 - 2019 Chairman, German Society of Hematology and Oncology (DGHO)  
2016 Walter-Siegenthaler Medal in gold  
2016 - present Member of the Medical Committee of the German Scientific Council (Wissenschaftsrat) of the German Government  
2014 - present Scientific Board, German Chamber of Physicians (Bundesärztekammer)  
2014 - 2015 President, German Society of Internal Medicine DGIM  
2014 - 2017 Scientific Committee, American Society of Hematology  
2014 President of the German Cancer Congress  
2013 Senate Commission "Grundsatzfragen der Klinischen Forschung", DFG  
2013 Binet-Rai-Medal of the International Workshop on CLL  
2013 - 2021 Chairman, Clinical Research Unit 286 "DNA damage response in CLL"  
2012 Paul Martini Prize  
2011 - present Member of the National Academy of Sciences Leopoldina

2009 - 2014	Chairman, Collaborative Research Center 832 on "Tumor Microenvironment"
2008	Center of Excellence in Oncology Award, Center for Integrated Oncology CIO
2000 - present	Scientific Committee (Core Group) International Working Group on CLL (iwCLL)
1999	Artur-Pappenheim-Price, German Society of Hematology and Oncology
1996 - present	Founder and Chairman, German CLL Study Group

### Selected publications

- Simon F, Ligtoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, Goede V, von Tresckow J, Langerbeins P, Fink AM, Huber H, Tausch E, Schneider C, Wendtner CM, Ritgen M, Dreyling M, Müller L, Jacobasch L, Heinz WJ, Vehling-Kaiser U, Sivcheva L, Böttcher S, Dreger P, Illmer T, Gregor M, Staber PB, Stilgenbauer S, Niemann CU, Kater AP, Fischer K, Eichhorst B, **Hallek M**, Al-Sawaf O. End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. *J Clin Oncol.* **2024** Aug 23;JCO2401192.
- Lewis RI, vom Stein AF, **Hallek M**. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia. *Blood* **2024**; Aug 8;144(6):601-614.
- Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, **Hallek M**, Cramer P. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial. *Blood.* **2024** Jul 18;144(3):272-282.
- Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivcheva L, Niemann CU, Schwarzer AP, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, **Hallek M**, Fischer K. Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study. *Blood.* **2024** Jul 10;blood.2024024631. doi: 10.1182/blood.2024024631. Epub ahead of print. PMID: 39082668.
- Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenbergh E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, **Hallek M**, Niemann CU, Eichhorst B. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* **2024** Jun;25(6):744-759.
- Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter M, Niemann CU, da Cunha-Bang C, Kater A, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, **Hallek M**. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies. *Blood.* **2024** Jun 20;143(25):2588-2598.
- Al-Sawaf O, Ligtoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, **Hallek M**, Eichhorst B. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. *Nat Med.* **2024** Jan;30 (1):240-248.
- Eichhorst B., Niemann C.U., Kater A.P., Fürstenau M., von Tresckow J., Zhang C., Robrecht S., Gregor M., Juliusson G., Thornton P., Staber P., Tadmor T., Lindström V., da Cunha-Bang C., Schneider C., Poulson C.B., Illmer T., Schöttker B., Nösslinger T., Janssens A., Christiansen I., Baumann M., Frederiksen H., van der Klift M., Jäger U., Leys M.B.L., Hoogendoorn M., Lotfi K., Hebart H., Gaska T., Koene H., Enggaard L., Goede J., Regelink J.C., Widmer A., Simon F., de Silva N., Bahlo J., Fischer K., Wendtner C.-M., Kreuzer K.A., Ritgen M., Brüggemann M., Tausch E., Levin M.-D., van Oers M., Geisler C., Stilgenbauer S., and **Hallek M**. First-line venetoclax-combinations in chronic lymphocytic leukemia. *N Engl J Med* **2023** 388 (19):1739-1754.

9. Al-Sawaf O., Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer K-A, Chyla B, Paulson J, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, **Hallek M**, Fischer K. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. *Nat Commun.* **2023** 14, 2147.
10. Vom Stein AF, Rebollido-Rios R, Lukas A, Koch M, von Lom A, Reinartz S, Bachurski D, Rose F, Bozek K, Abdallah AT, Kohlhas V, Saggau J, Zölzer R, Zhao Y, Bruns C, Bröckelmann PJ, Lohneis P, Büttner R, Häupl B, Oellerich T, Nguyen PH, **Hallek M**. LYN kinase programs. Stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1. *Nat Commun.* **2023**; 14, 1330.
11. Fischer, K., Al-Sawaf O., Bahlo J., Fink AM., Tandon M., Dixon M., Robrecht S., Warburton S., Humphrey K., Samoylova O., Liberati AM., Pinilla-Ibarz J., Opat S., Sivcheva L., Le Dû K., Fogliatto LM., Niemann CU., Weinkove R., Robinson S., Kipps TJ., Boettcher S., Tausch E., Humerickhouse R., Eichhorst B., Wendtner CM., Langerak AW., Kreuzer KA., Ritgen M., Goede V., Stilgenbauer S., Mobasher M., **Hallek M**. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Condition, *N Engl J Med.* 2019 Jun 6;380(23):2225-2236.
12. **Hallek, M.**, Shanafelt, T., Eichhorst, B. Chronic lymphocytic leukemia. *Lancet.* **2018** Apr 14;391(10129):1524-1537.
13. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozicl, Lawrence M, Bottcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Dohner H, **Hallek M**,\* Neuberger D,\* Getz G,\* Stilgenbauer S\* and Wu CJ\*. Mutations driving CLL and their evolution in progression and relapse. *Nature.* 2015, 526, 525-530. \*Joint senior authors.
14. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T., de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M and **Hallek M**. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med.* 2014, 370, 1101-1110.
15. Furman R.R, Sharman JP, Coutre SE, Cheson BD, Pagel, JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps, TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, **Hallek M** and O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med.* 2014, 370, 997-1007.
16. **Hallek M**, Fischer, K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trnety M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H and Stilgenbauer S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet.* 2010, 376, 1164-1174.
17. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, **Hallek M**, Van Etten RA, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B lymphoblastic leukemia but not chronic myeloid leukemia, *Nat Gen* 2004, 36 (5),453-461.

#### Patents

**Inventors:** Bünning H, Nieland J, Perabo L, Kühn D, Lux K, Hallek M, Hörer M, Ritter M

**Application #:** EP 2158488B1

**Title:** Mutated parvovirus structural proteins as vaccines

**Inventors:** Lux K, Bünning H, Perabo L, Nieland J, Boucas J, Hallek M, Ritter M, Hörer M

**Application #:** EP2158211B1

**Title:** Mutated structural protein of a parvovirus